MicroRNA-1 suppresses glioblastoma in preclinical models by targeting fibronectin

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Glioblastoma (GBM) is an aggressive brain cancer with limited treatment options.
• MicroRNAs (miRNAs) are crucial regulators of cancer cell behavior, but their specific roles in GBM tumorigenesis are not fully understood.
• Low expression of miR-1 has been observed in GBM patients.

Purpose of the Study:

• To investigate the role of miR-1 in glioblastoma.
• To identify the molecular targets of miR-1 in GBM.
• To evaluate the therapeutic potential of targeting the miR-1/fibronectin pathway in GBM.

Main Methods:

• Assessing miR-1 expression levels in GBM patient samples and cell lines.
• Overexpressing miR-1 in GBM cells and evaluating its effects on proliferation, migration, and apoptosis sensitivity.
• Identifying miR-1 targets using bioinformatics and experimental validation.
• Analyzing the correlation between miR-1 and fibronectin expression with patient survival.
• Knocking out fibronectin in GBM cells and assessing tumor growth and survival.
• Restoring fibronectin expression in miR-1 overexpressing cells.

Main Results:

• miR-1 expression is significantly lower in GBM compared to normal brain tissue.
• Ectopic miR-1 expression suppressed GBM cell proliferation and migration, enhanced temozolomide-induced apoptosis, and inhibited tumor growth in vivo.
• Fibronectin was identified as a direct target of miR-1 in GBM.
• High fibronectin expression correlated with poor patient survival and was inversely associated with miR-1 levels.
• Fibronectin knockout mimicked the tumor-suppressive effects of miR-1, while its restoration counteracted miR-1's effects.

Conclusions:

• miR-1 exhibits tumor-suppressive activity in glioblastoma by targeting fibronectin.
• The miR-1/fibronectin axis represents a promising therapeutic target for GBM treatment.
• Modulating this pathway could offer a novel strategy for managing this devastating brain cancer.